Clinical Trials Using Carvedilol

Clinical trials are research studies that involve people. The clinical trials on this list are studying Carvedilol. All trials on the list are supported by NCI.

NCI’s basic information about clinical trials explains the types and phases of trials and how they are carried out. Clinical trials look at new ways to prevent, detect, or treat disease. You may want to think about taking part in a clinical trial. Talk to your doctor for help in deciding if one is right for you.

Trials 1-4 of 4
  • Carvedilol for the Treatment of Heart Disease in Patients with New or Locally Recurrent Breast Cancer Receiving Trastuzumab, TACTIC Study

    This phase II trial studies how well carvedilol works in treating heart disease (cardiomyopathy) in patients with breast cancer that is new or has come back at or near the same place as the primary tumor (locally recurrent), who are planning to receive trastuzumab therapy. Carvedilol is a drug used to treat high blood pressure and certain heart problems and may help to treat heart disease in patients with breast cancer.
    Location: 4 locations

  • Carvedilol in Reducing the Risk of Cardiotoxicity in Patients with Stage I-III Breast Cancer Treated with Doxorubicin and / or Trastuzumab

    This phase I trial studies the side effects and best dose of carvedilol in reducing the risk of cardiotoxicity in patients with stage I-III breast cancer who are being treated with doxorubicin and / or trastuzumab. Some cancer treatments can cause damage to the heart. A risk calculator has been developed to predict the likelihood that this damage (called cardiotoxicity) will be experienced. This study is being conducted to test whether this calculator can be used to identify patients who may benefit from medicines to protect the heart and to test whether a medicine, called carvedilol, can be used to protect the heart during chemotherapy for patients who are identified as being at elevated risk.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania

  • Testing the Addition of a Blood Pressure Medication, Carvedilol, to HER-2 Targeted Therapy for Metastatic Breast Cancer to Prevent Cardiac Toxicity

    This phase III trial studies compares prophylactic beta blocker therapy with carvedilol versus no prophylaxis in preventing cardiac toxicity in patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body (metastatic). A beta-blocker, such as carvedilol, is used to treat heart failure and high blood pressure, and it may protect the heart from the side effects of chemotherapy.
    Location: 444 locations

  • Biomarker-Guided Cardioprotection in Patients with Lymphoma or Breast Cancer Treated with Anthracyclines

    This phase I / II trial investigates the feasibility of a biomarker-guided cardioprotection treatment in patients with lymphoma or breast cancer who are receiving anthracyclines. Anthracycline-based chemotherapy is commonly used to treat cancer but can damage the heart. The N-terminal pro-hormone of brain natriuretic peptide (NT-proBNP) is a heart-stress hormone that can be measured using a blood test. Patients who have weakened heart function often have high NT-proBNP levels. They may have high NT-proBNP levels even if they don’t have other symptoms of weakened heart function. This study aims to see whether NT-proBNP can be used as an “early warning sign” of heart damage in patients who are treated with anthracyclines.
    Location: University of Pennsylvania / Abramson Cancer Center, Philadelphia, Pennsylvania